NCT06245837Active, not recruiting
Treatment and Biomarker Testing Patterns,Treatment Outcomes in a/m NSCLC With and Without Actionable Genomic Alterations
Multicenter, Non-interventional, Observational Study of Treatment and Biomarker Testing Patterns, Treatment Outcomes in Advanced/Metastatic NSCLC With and Without Actionable Genomic Alterations in Routine Clinical Practice in Russia
Source: ClinicalTrials.gov · Last updated 15 Jun 2026
Brief summary (registry, in English)
Planned study population consists of approximately 1500 adult patients with a/m NSCLC in Russia, in about 20 oncological centers (in each center it is expected to recruit about 75 patients) in different regions of Russia in order to provide representative study sample
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 1500 (estimated)
- First submitted
- 18 Jan 2024
- Start date
- 20 Mar 2024
- Primary completion date
- 30 Jun 2026
- Lead sponsor
- AstraZeneca
- Diseases
- Lung cancer, Childhood cancers
- NCT number
- NCT06245837
What you commit to
- Study type: Observational
- Planned participants: 1500
- From 20 Mar 2024 to the primary completion date, 30 Jun 2026
- 16 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Diagnosis of another cancer (except for melanoma/skin cancer) at or within 5 years prior to NSCLC diagnosis or any ongoing systemic anti-cancer therapy regimen at the time of NSCLC diagnosis
Other
- Patients participated or participating in clinical trials or any early access program within period since the index date until the end of study period;
Who the study is looking for
- Morphologically confirmed NSCLC with or without actionable genomic alterations (AGA, i.e. EGFR, ALK, ROS1, NTRK, BRAF, MET exon 14 skipping, RET, ERBB2 (HER2), or KRAS)
- Age ≥18 years at the time of NSCLC diagnosis;
- Locally advanced or metastatic disease defined as incident stage IIIB/IIIC/IV NSCLC or stage I-IIIA then progressed to stage IIIB-IV disease and not eligible for curative-intent treatment (the date of progression is included in the database);
- Available data on at least one line of systemic therapy for advanced/metastatic disease within the period since January 2022 until January 2025;
- Patients may be alive or deceased at the time of medical record abstraction
Sex: All · Does not accept healthy volunteers
Sites (16)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.